1. patient currently hospitalized or under immediate consideration for hospitalization; 2. patient currently in shock or with hemodynamic instability; 3. patient with inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption; 4. patient with pre-existent progressive neuromuscular disease; 5. estimated glomerular filtration rate (egfr), using the mdrd equation for all subjects being considered for enrollment, with a cut-off of \< 30 ml/m in/1.73m2; 6. patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease; 7. female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication; 8. patient currently taking colchicine for other indications (mainly chronic indications represented by familial mediterranean fever or gout); 9. patient with a history of an allergic reaction or significant sensitivity to colchicine; 10. patient undergoing chemotherapy for cancer; 11. patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

1. patient currently hospitalized or under immediate consideration for hospitalization; 2. patient currently in shock or with hemodynamic instability; 3. patient with inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption; 4. patient with pre-existent progressive neuromuscular disease; 5. estimated glomerular filtration rate (egfr), using the mdrd equation for all subjects being considered for enrollment, with a cut-off of \< 30 ml/m in/1.73m2; 6. patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease; 7. female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication; 8. patient currently taking colchicine for other indications (mainly chronic indications represented by familial mediterranean fever or gout); 9. patient with a history of an allergic reaction or significant sensitivity to colchicine; 10. patient undergoing chemotherapy for cancer; 11. patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

patient currently hospitalized or under immediate consideration for hospitalization; patient currently in shock or with hemodynamic instability; patient with inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption; patient with pre-existent progressive neuromuscular disease; estimated glomerular filtration rate (egfr), using the mdrd equation for all subjects being considered for enrollment, with a cut-off of < 30 ml/m in/1.73m2; patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease; female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication; patient currently taking colchicine for other indications (mainly chronic indications represented by familial mediterranean fever or gout); patient with a history of an allergic reaction or significant sensitivity to colchicine; patient undergoing chemotherapy for cancer; patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

patient currently hospitalized or under immediate consideration for hospitalization; patient currently in shock or with hemodynamic instability; patient with inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption; patient with pre-existent progressive neuromuscular disease; estimated glomerular filtration rate (egfr), using the mdrd equation for all subjects being considered for enrollment, with a cut-off of < 30 ml/m in/1.73m2; patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease; female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication; patient currently taking colchicine for other indications (mainly chronic indications represented by familial mediterranean fever or gout); patient with a history of an allergic reaction or significant sensitivity to colchicine; patient undergoing chemotherapy for cancer; patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

1. patient currently hospitalized or under immediate consideration for hospitalization; 2. patient currently in shock or with hemodynamic instability; 3. patient with inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption; 4. patient with pre-existent progressive neuromuscular disease; 5. estimated glomerular filtration rate (egfr), using the mdrd equation for all subjects being considered for enrollment, with a cut-off of < 30 ml/m in/1.73m2; 6. patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease; 7. female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication; 8. patient currently taking colchicine for other indications (mainly chronic indications represented by familial mediterranean fever or gout); 9. patient with a history of an allergic reaction or significant sensitivity to colchicine; 10. patient undergoing chemotherapy for cancer; 11. patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

1. patient currently hospitalized or under immediate consideration for hospitalization; 2. patient currently in shock or with hemodynamic instability; 3. patient with inflammatory bowel disease (crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption; 4. patient with pre-existent progressive neuromuscular disease; 5. estimated glomerular filtration rate (egfr), using the mdrd equation for all subjects being considered for enrollment, with a cut-off of < 30 ml/m in/1.73m2; 6. patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease; 7. female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication; 8. patient currently taking colchicine for other indications (mainly chronic indications represented by familial mediterranean fever or gout); 9. patient with a history of an allergic reaction or significant sensitivity to colchicine; 10. patient undergoing chemotherapy for cancer; 11. patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.